A press release yesterday announced New York City law firm of Rheingold, Giuffra, Ruffo & Plotkin LLP (RGRP) commenced two wrongful death lawsuits against the makers of Xarelto. Each suit involved the death of a user of the blood thinner Xarelto. As reported by Reuters, CBS MarketWatch and over 200 other business and news organizations, each Xarelto lawsuit alleged that the drug is misleadingly marketed as a “one size fits all” for patients, and without a disclosure that there is no reversal agent available to arrest bleeding once it starts. You can find the press release in its entirety here.
Both of the firm’s clients had been recently started on Xarelto and rapidly developed bleeding in the brain. Although hospital doctors tried to use standard methods to reverse the bleeding, there turned out not to be a remedy for a Xarelto-induced bleed, as there is for the more established drug used to control clotting, Coumadin (warfarin).
The two lawsuits were filed by Paul Rheingold, Esq, who founded RGRP and has been in practice since 1958. His litigation focus for many years has been mass torts. In fact, Paul organized the first mass tort drug case, involving a cholesterol-lowering drug known as MER/29.
RGRP is a national firm located in New York City, handling personal injury cases including mass torts, a field which includes the Xarelto litigation. The Rheingold law firm is also investigating a separate type of injury attributable to the use of Xarelto: hepatocellular liver damage. A recent medical article in the JAMA Internal Medicine magazine reported on two cases associated with the use of the drug.
If you or someone close to you has been injured by Xarelto, contact Paul Rheingold at: (212) 684-1880 or online here.